Literature DB >> 20618113

Fifteen years of bowel cancer screening policy in Australia: putting evidence into practice?

Kathy L Flitcroft1, Glenn P Salkeld, James A Gillespie, Lyndal J Trevena, Les M Irwig.   

Abstract

Bowel cancer kills over 4000 Australians each year. From the late 1980s to October 2005, research evidence guided the development of bowel cancer screening policy proposals, but political, financial and institutional constraints restricted implementation options. Since 2006, the Australian Government has provided a limited bowel cancer screening program, based on what the government deems it can afford, rather than on evidence of what is required to implement a successful population-based screening program. Even a partial program can be implemented in an evidence-based way, and failure to do so threatens to undermine the potential public health gains of a national bowel cancer screening program. To realise the expected public health gains from a national bowel cancer screening program, bowel cancer screening policy should return to its evidence-based beginnings, starting with an analysis of Australian age-specific cost-effectiveness data.

Entities:  

Mesh:

Year:  2010        PMID: 20618113     DOI: 10.5694/j.1326-5377.2010.tb03739.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  9 in total

1.  Screening practices of unaffected people at familial risk of colorectal cancer.

Authors:  Driss Ait Ouakrim; Alex Boussioutas; Trevor Lockett; Ingrid Winship; Graham G Giles; Louisa B Flander; Louise Keogh; John L Hopper; Mark A Jenkins
Journal:  Cancer Prev Res (Phila)       Date:  2011-10-26

Review 2.  A comparative case study of bowel cancer screening in the UK and Australia: evidence lost in translation?

Authors:  K L Flitcroft; D J B St John; K Howard; S M Carter; M P Pignone; G P Salkeld; L J Trevena
Journal:  J Med Screen       Date:  2011-11-21       Impact factor: 2.136

3.  Screening practices of Australian men and women categorized as "at or slightly above average risk" of colorectal cancer.

Authors:  Driss Ait Ouakrim; Trevor Lockett; Alex Boussioutas; Louise Keogh; Louisa B Flander; Ingrid Winship; Graham G Giles; John L Hopper; Mark A Jenkins
Journal:  Cancer Causes Control       Date:  2012-09-26       Impact factor: 2.506

4.  Costs and cost-effectiveness of full implementation of a biennial faecal occult blood test screening program for bowel cancer in Australia.

Authors:  Michael P Pignone; Kathy L Flitcroft; Kirsten Howard; Lyndal J Trevena; Glenn P Salkeld; D James B St John
Journal:  Med J Aust       Date:  2011-02-21       Impact factor: 7.738

5.  Measurement in comparative effectiveness research.

Authors:  Jessica Chubak; Carolyn M Rutter; Aruna Kamineni; Eric A Johnson; Natasha K Stout; Noel S Weiss; V Paul Doria-Rose; Chyke A Doubeni; Diana S M Buist
Journal:  Am J Prev Med       Date:  2013-05       Impact factor: 5.043

6.  Colorectal cancer screening knowledge, attitudes and behavioural intention among Indigenous Western Australians.

Authors:  Aliki Christou; Sandra C Thompson
Journal:  BMC Public Health       Date:  2012-07-18       Impact factor: 3.295

7.  A prospective multiple case study of the impact of emerging scientific evidence on established colorectal cancer screening programs: a study protocol.

Authors:  Hannah Geddie; Mark J Dobrow; Jeffrey S Hoch; Linda Rabeneck
Journal:  Implement Sci       Date:  2012-06-01       Impact factor: 7.327

8.  Engagement of General Practice in an Australian Organised Bowel Cancer Screening Program: A Cross-Sectional Survey of Knowledge and Practice.

Authors:  Carol A Holden; Oliver Frank; Ming Li; Ramesh Manocha; Joanna Caruso; Deborah Turnbull; Richard L Reed; Caroline L Miller; David Roder; Ian Olver
Journal:  Asian Pac J Cancer Prev       Date:  2020-07-01

9.  Is England closing the international gap in cancer survival?

Authors:  Sarah Walters; Sara Benitez-Majano; Patrick Muller; Michel P Coleman; Claudia Allemani; John Butler; Mick Peake; Marianne Grønlie Guren; Bengt Glimelius; Stefan Bergström; Lars Påhlman; Bernard Rachet
Journal:  Br J Cancer       Date:  2015-08-04       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.